MR imaging-guided focal laser ablation for prostate cancer: Phase I trial

Radiology

Volumn 267, Issue 3, 2013, Pages 932-940

  Oto, Aytekin ^a   Sethi, Ila ^a   Karczmar, Gregory ^a   McNichols, Roger ^b   Ivancevic, Marko K ^c   Stadler, Walter M ^a   Watson, Sydeaka ^a   Eggener, Scott ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Visualase Inc   (United States)

^c PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; IMAGING SOFTWARE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LASER THERMOTHERAPY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; PARESTHESIA; PATIENT SAFETY; PENIS GLANS; PERINEAL ABRASION; PERINEUM INJURY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SEXUAL HEALTH INVENTORY FOR MEN; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE;

AGED; BIOPSY; CONTRAST MEDIA; FEASIBILITY STUDIES; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LASER THERAPY; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84878331005     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121652     Document Type: Article

References (20)

1. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185(3):869-875.
2. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 2007;67(1):57-64. (Pubitemid 44959493)
3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250- 1261. (Pubitemid 351439226)
4. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878. (Pubitemid 36833878)
5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28(1):126-131.
6. Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010;58(1):57-64.
7. Arumainayagam N, Moore CM, Ahmed HU, Emberton M. Photodynamic therapy for focal ablation of the prostate. World J Urol 2010;28(5):571-576.
8. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality - clinical implications. Technol Cancer Res Treat 2007;6(1):37-48. (Pubitemid 46389347)
9. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep 2010;11(3):147-151.
10. Stafford RJ, Shetty A, Elliott AM, et al. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol 2010;184(4):1514-1520.
11. Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 2010;57(6):1111-1114.
12. De Poorter J. Noninvasive MRI thermometry with the proton resonance frequency method: study of susceptibility effects. Magn Reson Med 1995;34(3):359-367.
13. Hindman JC. Proton resonance shift of water in gas and liquid states. J Chem Phys 1966;44(12):4582-4592.
14. Ishihara Y, Calderon A, Watanabe H, et al. A precise and fast temperature mapping method using water proton chemical shift [abstr]. In: Book of abstracts: Society of Magnetic Resonance in Medicine 1992. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1992; 4803.
15. Quesson B, de Zwart JA, Moonen CT. Magnetic resonance temperature imaging for guidance of thermotherapy. J Magn Reson Imaging 2000;12(4):525-533.
16. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984;10(6):787-800. (Pubitemid 14094055)
17. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005;17(4):307-319. (Pubitemid 41025762)
18. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549-1557; discussion 1564.
19. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185(4):1246-1254.
20. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009;182(4):1371-1377.